Huayuan Securities released a research report on April 25 stating that it gave Baike Biotech (688276.SH) a purchase rating. The main reasons for the rating include: 1) the burden of shingles disease is high, with more than 1.5 million new cases per year; 2) vaccine products have a good domestic competition pattern and huge market potential; 3) the two technical routes of recombination/attenuation each have advantages. In the context of the huge blue ocean market, we are optimistic about the future market space for the two products. (Mainichi Keizai Shimbun)
华源证券4月25日发布研报称，给予百克生物（688276.SH）买入评级。评级理由主要包括：1）带状疱疹疾病负担较大，国内每年新发病例超150万人；2）疫苗产品国内竞争格局良好，市场潜力巨大；3）重组/减毒两种技术路线各有优势，巨大蓝海市场背景下，我们看好两款产品未来市场空间。（每日经济新闻）
Huayuan Securities released a research report on April 25 stating that it gave Baike Biotech (688276.SH) a purchase rating. The main reasons for the rating include: 1) the burden of shingles disease is high, with more than 1.5 million new cases per year;
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.